This is a study in Sydney Local Health District of Community Health Navigators (CHNs) providing follow up care for patients as they move hospital to the community. The first phase of the study is a co-design stage that involve the key stakeholders working together to identify training and supervision needs. The second phase is a randomised trial evaluating the impact of CHN follow up following discharge from hospital.
Prof Mark Harris, Prof Parisa Aslani (USyd) A/Prof Jean-Frederic Levesque (ACI), A/Prof Margo Barr, Dr Anurag Sharma (SPH, UNSW), A/Prof Ben Harris-Roxas, Dr Michael Wright (CHERE, UTS), Prof Richard Osborne (University of Swinburn)
Ms Sharon Parker
Ms An Tran
Ms Lou-Anne Blunden (SLHD), Dr John Cullen (SLHD), Deb Donnelly (SLHD), Ms Julie Finch (SLHD), Dr Brendan Goodger (CESPHN), A/Prof Fiona Haigh, A/Prof Elizabeth Harris, Ms Regina Osten (ACI), Dr Antony Brown (HCNSW), Dr Sara Javanparast (Flinders University)
Ms An Tran, Ms Margaret Williamson
Dr Fiona Doolan Noble (University of Otago NZ), Dr. Simone Dahrouge, (Ottawa, Canada), Dr Sara Javanparast (Flinders University) Dr. Pim Valentijn (Maastricht University, Netherlands)
This study addresses a major challenge of the health system in dealing with people with multiple long-term conditions and vulnerabilities. As well as suffering limitation to their own quality of life, these patients are at risk of hospitalisation and re-hospitalisation due to a range of
problems including medication errors, poor self-management and limited access to care. This places a significant burden on the health system.
To develop, implement and evaluate the impact of a CHN delivered model of care supporting transition of care from hospital to community for patients who are aged or have chronic conditions on patient health and health service outcomes (including readmission).
The project will be undertaken in three stages.
Stage 1: Co-design of CHWs selection, training and activities.
The first phase of the study is a co-design stage that involve the key stakeholders working together and contributing their different perspectives to come up with the best solution. This will define the training, supervision and support that the CHNs will need and how the project should be implemented in SLHD. In this stage it is important that we have involvement of:
The codesign phase will commence with interviews with participants. This will be followed by workshops to review what has been found from the interviews and consultations.
Stage 2. Intervention trial
A pragmatic randomised controlled trial will then be undertaken. Patients will be identified by the SLHD staff using their database of in-patients at four public hospitals and then approached in-hospital by research staff who will obtain written consent and interview the participants. The CHN will visit the patient while in hospital and then in two home visits and two phone calls. During these visits the CHN will provide non-medical support for self-management, medicine reconciliation and access to appropriate health and non-health services. Evaluation will be based on routinely collected hospitalisation, GP and Pharmaceutical Benefits scheme data, patient and provider surveys and qualitative interviews.
Phase 3. Translation
Based on the findings we will identify conditions for sustainability and translation to other Local Health Districts in NSW and in Australia and overseas.
Trial Coordinator: Sharon Parker, phone +61 (2) 9065 6733
Research Officer: An Tran, phone +61 (2) 9065 2326
Sydney Local Health District (SLHD), Agency for Clinical Innovation (ACI), Central and Eastern Sydney Primary Health Network (CESPHN), Health Consumer NSW (HCNSW) , University of Otago, New Zealand, University of Ottawa, Canada, Flinders University, Maastricht University, Netherlands